NEW YORK--(BUSINESS WIRE)--May 10, 2006--FermaVir Pharmaceuticals, Inc. (OTCBB: FMVR - News) is pleased to announce that Professor Chris McGuigan, a FermaVir founder and board member gave an oral presentation this morning entitled: “PreClinical Development of the BCNA’s: The Most Potent Anti-VZV Agents Reported to Date” at the 19th International Conference on Antiviral Research. Professor McGuigan presented the most recent preclinical data on FermaVir’s clinical candidate for shingles, FV-100. FV-100, a Prodrug of the compound CF-1743, showed an 8-10 fold increase in bioavailability in a preclinical study. The work presented is a three-way collaboration between the company, Cardiff University, Cardiff, Wales and the Rega Institute of the Katholieke Universiteit, Leuven, Belgium.
